Side-by-side · Research reference

EpitalonvsKisspeptin-10

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED3/37 cited

BPhase 2HUMAN-REVIEWED10/41 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle dose

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

Kisspeptin-10

Neuropeptide · GPR54 Agonist

GnRH pulse generatorPrimary roleSilva 2026

Phase 1/2Clinical stage

GPR54/Kiss1RTarget receptorRønnekleiv 2026

IV / SQ · Investigational

01Mechanism of Action

Parameter

Epitalon

Kisspeptin-10

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026 Collado-Sole 2026

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatonin

Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026 Rønnekleiv 2026

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged mice

Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026

Feedback intact?

—

Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026 Rønnekleiv 2026

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)

C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms

Antibody development

—

02Dosage Protocols

Parameter

Epitalon

Kisspeptin-10

Standard dose

5–10 mg / day for 10–20 days, 1–2× per year

Anecdotal community protocol. Russian clinical literature uses similar cycling.

—

Frequency

Once daily during a cycle

—

Lower / starter dose

2.5 mg / day

—

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Phase 1/2 trials

Duration

10–20 day cycles, 1–2× per year

—

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep preferred (pineal alignment)

—

Half-life

Hours (estimated)

Short (minutes)

Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.

Clinical trial dose

—

Phase 1/2 investigational

Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).

Route

—

IV or SQ administration

IV preferred in controlled trials for precise pulsatile delivery.

04Side Effects & Safety

Parameter

Epitalon

Kisspeptin-10

Injection site reaction

Mild irritation

Erythema, mild discomfort (SQ route)

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

—

Antibody formation

Not reported

—

Ovarian hyperstimulation

—

Theoretical risk with supraphysiological dosing in fertility protocols

Headache

—

Mild, reported in early-phase trials

Nausea

—

Transient GI symptoms with IV bolus

Hot flashes

—

Vasomotor symptoms from LH surge

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Kisspeptin-10

·Active pregnancy
·Hormone-sensitive malignancy (breast, ovarian, endometrial)

Relative Contraindications

Epitalon

·Family history of cancer

Kisspeptin-10

·Polycystic ovary syndrome (PCOS) without monitoring
·Uncontrolled thyroid dysfunction

05Administration Protocol

Parameter

Epitalon

Kisspeptin-10

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.

2. Injection site

SQ — abdomen preferred. Rotate sites.

IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.

3. Timing

Pre-sleep preferred to align with pineal axis.

Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.

5. Needle

29–31G, 4–8 mm insulin syringe.

Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.